Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? - Wikidata - wikimedia - TriplyDB

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

http://www.wikidata.org/entity/Q38190678

about

Reviewing 15 years of experience with sirolimus Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?The need for minimization strategies: current problems of immunosuppression.Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients.mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside.Transplantation: CNIs to mTOR inhibitors--effects on allosensitization?

P2860

Q28080955-08BC8488-D0AD-4878-8189-B61C2C1279FA Q33617408-294E033A-1393-4844-9437-6C608617150F Q36087779-BD588306-8C7F-4B7D-B637-09A2EFA9C839 Q38370826-93314DB3-7504-49C8-A6C4-9893A14ED1E6 Q41313340-4408120B-34E1-4DE7-AC69-C68D80147E06 Q41472979-6EF19B28-4147-44F9-B87C-C318C5DA6B2B Q42418219-8CD66E27-F623-48EE-939B-66361584E506 Q46764150-6A3F53B2-5B48-468D-9656-A4B3BF922027 Q54349986-3C1BA0E7-8406-4F4C-A79E-F58AAE2FAC23

P2860

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

http://www.wikidata.org/entity/Q38190678

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

@en

type

label

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

@en

prefLabel

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

@en

P1433

Q38190678-18611BC5-489A-44CB-AFE9-827A2870ED92

P1476

Q38190678-D3BE5D71-2C85-4031-87FB-4EB018B0973F

P2093

Q38190678-9C290FD9-8CC9-4C52-91E6-E3604485BECE

P2860

Q38190678-1146CC6D-B9EF-4B94-9275-2E2F8D6DF49A

Q38190678-1D4D83F4-A55F-444F-9461-7F4EE69B8B15

Q38190678-2EB7C682-D34D-49FD-8DCB-5D117CD170D7

Q38190678-3456E51C-2862-4132-9ACD-FCFFECA27B86

Q38190678-3ABCD365-FBF0-4E12-B8BE-251507AFF85B

Q38190678-3FDF3776-E207-42B2-9601-3350CC85B307

Q38190678-457A4CD6-BCD8-401B-AC4A-7C1F784A14CE

Q38190678-595ABEE4-CA38-490F-B7F3-315D2913D140

Q38190678-5BE4A63E-5691-42BC-853E-F29EC416D728

Q38190678-5E472764-E2D4-4F27-9EB9-5A97EA8B9D43

P2888

Q38190678-2A8C58D5-0500-47D4-AF4B-24F86D369DA9

P304

Q38190678-CAC26083-E6D9-4AC4-AE9B-9654CD22053C

P31

Q38190678-C76FB4D0-1F2B-4B65-B31A-3B084A85DBA2

P356

Q38190678-8F7FEC60-6C86-48E9-AD90-D862B60A4D7B

P433

Q38190678-6095FB45-2737-45FF-9B4C-D9377C772E61

P478

Q38190678-C7ABFEE4-FE13-43B1-A458-8603051CC669

P50

Q38190678-E297EB50-FEF9-4E33-A167-718DF20F3996

P577

Q38190678-A85AD5EC-56C4-42E9-8BCD-BA5965BB829C

P5875

Q38190678-553075C3-2FFB-4228-9E10-23BA5D312324

P6179

Q38190678-35C5642F-51D9-4CC7-A4A6-99F177D36F92

P698

Q38190678-587ECC3A-5C2B-45FE-89DD-22D31F54EFD9

P921

Q38190678-CAB80599-94CD-4C65-AF7F-D01A14891347

P932

Q38190678-43E07D54-A9E3-46CD-AF62-8FCC0962F60C

P356

2047-1440-2-S1-S3

P1433

Transplantation research

P1476

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

@en

P2093

Philippe Gatault

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Chronic renal allograft dysfunction.

Calcineurin inhibitor-free immunosuppression in kidney transplantation.

mTOR, cancer and transplantation.

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.

Long-term renal allograft survival in the United States: a critical reappraisal.

Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.

P2888

2047-1440-2-s1-s3

P304

S3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2047-1440-2-S1-S3

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260377751

http://www.w3.org/2001/XMLSchema#string

P6179

1006064555

http://www.w3.org/2001/XMLSchema#string

P698

24565231

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

3834549

http://www.w3.org/2001/XMLSchema#string